Intermittent Hypoxia Composite Abnormal Glucose Metabolism-Mediated Atherosclerosis In Vitro and In Vivo: The Role of SREBP-1

Figure 2

Schematic diagram of IH treatment (in vitro) and CIH treatment (in vivo). (a) Schematic diagram of IH treatment (in vitro); (b) IH treatment cycle pattern (in vitro); (c) schematic diagram of CIH treatment (in vivo); (d) CIH treatment hypoxia cycle pattern (in vivo).

(a)

(b)

(c)

(d)